Inflammation sits at the centre of nearly every common skin complaint — acne, eczema, psoriasis, rosacea, and the slower, less visible process of skin aging driven by chronic low-grade inflammation. Omega-3 fatty acids are consistently discussed as an anti-inflammatory intervention, but the mechanism matters more than the category. EPA and DHA do not suppress inflammation the way ibuprofen does. They produce a distinct class of lipid mediators — resolvins, protectins, and maresins — that actively orchestrate the resolution of inflammatory cascades. That distinction between suppression and resolution is the reason the biology of omega-3s is worth understanding properly, and it changes what you should and should not expect from supplementation.

What follows is not a supplement recommendation. It is a review of the mechanism, the human trial evidence, the honest limits of that evidence, and what it means in practice — particularly for people tracking their skin through continuous biological monitoring.

The Mechanism — Eicosanoids, Resolution, and Why It Matters

To understand what EPA and DHA do, it helps to start with arachidonic acid (AA). AA is an omega-6 fatty acid that sits in cell membranes throughout the body. When a cell is stressed or damaged, AA is released from the membrane and enters the eicosanoid synthesis pathway — processed by two key enzymes, cyclooxygenase (COX) and lipoxygenase (LOX), into a family of potent pro-inflammatory signaling molecules. Mechanistic

The two eicosanoids most relevant to skin are prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). PGE2 drives vasodilation, redness, and pain sensitisation. LTB4 is a powerful neutrophil chemoattractant — it recruits the white blood cells responsible for the pustular inflammation seen in acne and the acute flares of eczema. Both are measurable in inflamed skin tissue, and both are elevated in active inflammatory skin conditions relative to healthy controls. Human study¹

EPA competes with AA for access to the COX and LOX enzymes. Because EPA occupies the same enzymatic pathway, it displaces AA and reduces total PGE2 and LTB4 output. But the eicosanoids EPA itself produces through these enzymes — PGE3, LTB5 — are structurally weaker pro-inflammatory signals. The net effect is a shift toward less potent inflammatory mediators, not simply a block. Mechanistic

The more distinctive contribution of EPA and DHA, however, is the production of specialized pro-resolving mediators (SPMs): resolvins of the E-series (from EPA) and D-series (from DHA), protectins, and maresins. SPMs are not anti-inflammatory in the conventional sense — they do not block inflammatory signaling. Instead, they actively direct the resolution phase: stimulating neutrophil apoptosis, promoting macrophage clearance of debris, and signaling the local environment to return to homeostasis. Human study²

This distinction matters clinically. An NSAID removes the ignition signal. A resolvin clears the fire. Chronic inflammatory states — including the low-grade skin inflammation that underlies conditions like eczema and acne — are characterised not only by excess inflammatory signaling but by impaired resolution. SPMs address the second problem. NSAIDs do not.

EPA/DHA and Systemic Inflammation — Human Evidence

The systemic anti-inflammatory effects of EPA and DHA supplementation are among the most replicated findings in nutritional science. A landmark 2015 review by Calder examined more than 30 randomised controlled trials and found consistent evidence that supplementation with 2g+ EPA+DHA daily reduces circulating levels of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) — three of the most widely used markers of systemic inflammation. Human study³

Dose and duration

Effects are dose-dependent. Doses below 1g EPA+DHA daily show weaker or inconsistent anti-inflammatory signal. Meaningful changes in circulating eicosanoid profiles require 8–12 weeks of consistent supplementation — the time needed for EPA to accumulate in cell membranes at concentrations sufficient to compete effectively with AA. Studies shorter than eight weeks or using lower doses are less likely to detect an effect, which partly explains the mixed results in the omega-3 literature. Human study³

SPM production confirmed in humans

A 2018 paper by Serhan and colleagues confirmed that SPM production in humans increases following omega-3 supplementation, measured in peripheral blood. Human study⁴ This is not merely a mechanistic inference — SPMs are detectable and quantifiable in human blood following supplementation. The finding closes the chain from dietary EPA/DHA intake to actual resolution biology in vivo.

Omega-3s and Skin Specifically

The systemic inflammation evidence is robust. The skin-specific human evidence is more limited but directionally consistent — and biologically coherent given what we know about eicosanoids and skin inflammation.

Acne

A 2011 pilot RCT by Pilkington and colleagues gave participants 2g EPA daily for 12 weeks and measured acne lesion counts and LTB4 levels in lesional skin. Both decreased significantly relative to placebo. Human study⁵ This is meaningful because LTB4 is a primary driver of neutrophil recruitment to follicular units — the mechanism behind pustular acne. Reducing LTB4 in the skin is a plausible upstream intervention, not a cosmetic one. The study was small (n=45) and should be treated as hypothesis-confirming rather than definitive.

Eczema (atopic dermatitis)

Bjørneboe and colleagues demonstrated in 1989 that 10g/day fish oil over 12 weeks produced a modest but statistically significant reduction in itch and scaling compared to placebo in patients with atopic dermatitis. Human study⁶ The dose was high by modern standards, and the study predates current atopic dermatitis outcome measures. Subsequent trials have shown variable results — some positive, some null — partly due to inconsistency in dose, duration, and outcome measures.

Psoriasis

A 2014 review by Millsop and colleagues found that EPA supplementation in psoriasis patients is associated with reductions in pruritus and scaling — additive to standard therapy but not a replacement for systemic treatment. Human study⁷ The mechanistic rationale is direct: LTB4 drives psoriatic plaque inflammation, and EPA reduces LTB4 synthesis.

Skin barrier and DHA

DHA is the dominant structural polyunsaturated fatty acid (PUFA) in the stratum corneum cell membranes. Adequate tissue DHA status is associated with lower transepidermal water loss (TEWL) — a measure of barrier integrity — and lower DHA status is associated with increased TEWL. Mechanistic Caveat — the causal direction of the DHA-TEWL relationship is not definitively established in prospective human trials; this remains a plausible mechanistic association.

A note on study quality

The honest assessment of the skin-specific RCT literature: most studies are small (n < 60), old, and use outcome measures that vary significantly between trials. There are no large, pre-registered RCTs powered to detect clinically meaningful skin endpoints. The mechanistic case is strong. The clinical evidence is supportive but not conclusive.

ALA, EPA, DHA — the Conversion Problem

The most common plant-based omega-3 is alpha-linolenic acid (ALA), found in flaxseed, walnuts, chia seeds, and hemp. ALA is an 18-carbon omega-3 fatty acid; EPA and DHA are 20- and 22-carbon, respectively. The body can elongate and desaturate ALA to produce EPA and DHA, but the conversion efficiency is poor.

In healthy adults, approximately 5–8% of dietary ALA converts to EPA. Conversion to DHA is even lower — typically under 1%, and in some studies as low as 0.5%. Human study⁸ The enzymes responsible for this conversion (delta-6 and delta-5 desaturases) are shared with the omega-6 pathway and are competitively inhibited by high linoleic acid intake — which characterises most Western diets. The result is that even generous ALA consumption from plant foods does not reliably raise tissue EPA+DHA to the levels associated with anti-inflammatory benefit in RCTs.

Ahiflower — a better plant source?

Ahiflower seed oil (Buglossoides arvensis) contains roughly 20% stearidonic acid (SDA), an 18-carbon omega-3 that enters the elongation pathway one step downstream of ALA, bypassing the rate-limiting delta-6 desaturase step. SDA-to-EPA conversion is more efficient — approximately 17% in human studies — making Ahiflower a meaningfully better plant-based route to EPA than ALA-rich oils. Human study It does not, however, match direct marine or algae EPA+DHA supplementation for achieving anti-inflammatory tissue levels.

For vegetarians and vegans

Algae-derived EPA+DHA is the cleanest plant-based option — it bypasses the conversion problem entirely, since marine EPA and DHA originate from algae in the first place. Algae oils are now available in triglyceride form with bioavailability comparable to fish oil.

The Gut-Skin Connection — Omega-3s and the Microbiome

EPA and DHA do not act in isolation. A 2018 study by Watson and colleagues showed that omega-3 supplementation modulates gut microbiome composition in humans — increasing Bifidobacterium and Lactobacillus species and reducing pro-inflammatory pathobionts. Human study⁹ This is relevant to skin because the gut-skin axis operates through systemic inflammatory load — when gut-derived inflammation decreases, the downstream skin signal typically follows with a 48–72 hour lag.

Mechanistically, a healthier microbiome composition → reduced gut permeability → reduced systemic lipopolysaccharide (LPS) translocation → reduced systemic inflammatory burden → reduced inflammatory input to skin. Mechanistic Whether omega-3-driven microbiome changes contribute meaningfully to skin outcomes has not yet been tested in a head-to-head RCT designed specifically to test this pathway. It is a plausible contributing mechanism, not an established one.

Honest Limits

The evidence base for omega-3s and skin is compelling but not complete. Several limitations deserve explicit acknowledgement.

• The landmark skin RCTs are old, small, and used doses not practical for most people. Bjørneboe's 1989 eczema trial used 10g/day fish oil — a dose that would be difficult to maintain and is associated with GI side effects in many people. Most modern supplements are 1–3g per capsule; the RCT doses require multiple daily capsules of concentrated EPA.
• No large head-to-head RCTs vs. standard dermatological treatment. Omega-3 supplementation has not been compared directly to topical steroids, dupilumab, or standard acne therapies in adequately powered trials. The question of whether it adds meaningfully to existing treatment has not been answered at scale.
• Fish oil oxidation is a real risk. EPA and DHA are highly unsaturated and prone to oxidation — particularly in capsule form stored at room temperature for extended periods. Oxidised EPA/DHA produces pro-inflammatory aldehydes. Poorly stored or old fish oil capsules may paradoxically worsen inflammatory load. IFOS certification (independent oxidation testing) or algae-based sources reduce this risk meaningfully.
• Publication bias is likely. Positive omega-3 trials are more likely to be published than null trials. The actual effect size in skin conditions may be smaller than the published literature suggests.

How to Use It

If you are considering omega-3 supplementation with skin outcomes in mind, the practical evidence points in a consistent direction.

Dose

2–3g EPA+DHA daily for a meaningful anti-inflammatory effect. Doses below 1g are more relevant to cardiovascular health than to skin inflammation. The dose in milligrams refers to combined EPA+DHA content — not total fish oil weight, which is often three to four times higher on labels.

Form

Triglyceride-form fish oil is better absorbed than ethyl ester form — absorption is approximately 70% higher in the presence of dietary fat. Krill oil provides EPA+DHA in phospholipid form, which may also be well-absorbed at lower doses. Algae oil is the vegan-equivalent and is the source from which fish EPA/DHA ultimately derives.

Duration

Allow 8–12 weeks for measurable changes in eicosanoid profiles. Skin effects, where they occur, may take 12–16 weeks. Stopping supplementation after four weeks and concluding it doesn't work is the most common error in self-experimentation with omega-3s.

Storage

Refrigerate after opening. Buy small quantities and use within three months of opening. A rancid fish oil smell indicates oxidation — discard and replace. Enteric-coated capsules reduce fishy aftertaste but do not prevent oxidation.

What SenseMe Tracks That Omega-3 Is Targeting

SenseMe's Sense Band reads heart rate variability (HRV) and electrodermal activity (EDA) continuously — both reflect the state of the autonomic nervous system, and both are inversely associated with systemic inflammatory burden. As EPA and DHA reduce the systemic inflammatory load over 8–12 weeks, HRV tends to improve over the same timeframe in people whose baseline autonomic tone is suppressed by inflammation. This is not a causal claim in your specific case — it is a pattern consistent with the mechanistic literature. Caveat — individual HRV response to omega-3 supplementation varies significantly; no RCT has used SenseMe specifically as an outcome measure.

The SenseMe app's Heart and Recovery domain scores reflect cardiovascular and autonomic state — the same biology that omega-3s are thought to support through their eicosanoid and resolvin pathways. The Skin domain score tracks the downstream skin signal: if systemic and gut inflammation are declining, the skin score may follow with a lag consistent with the gut-skin delay of 48–72 hours.

This is not a clinical trial. There is no control group in your daily life. But it is a personal feedback loop with daily resolution — a signal in your own biology rather than a population-level average — and it is more actionable than waiting eight weeks for a blood draw. Omega-3 supplementation may support your autonomic health, your skin barrier, and your inflammatory baseline. SenseMe can tell you whether the numbers in your own body are moving in that direction, in real time.

Claims language: omega-3 supplementation may support / is linked to / can contribute to reduced inflammatory markers and improved skin outcomes. It does not treat, cure, or prevent any skin condition. Consult a dermatologist for clinical management of eczema, psoriasis, or acne.